Search

Displaying results 2311 - 2320 of 10000 in total
  1. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis. … PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis.

  2. Drug

    Esterified estrogens

    go.drugbank.com/drugs/DB09381
    Approved

    Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. … Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.

  4. Drug

    Iophendylate

    go.drugbank.com/drugs/DB01187
    Approved

    Iophendylate is a mixture of isomers used as contrast medium, mainly for brain and spinal cord visualization. Iophendylate is a myelographic oil-ester (U.S. Patent 2,348,231). … A number of clinicians have published on the dangers of oil myelography.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: Ethyl 10-(p-iodophenyl)-undecanoate, Ethyl 10-(p-iodophenyl)undecylate
  5. Drug

    2-(5-fluoro-pentyl)-2-methyl-malonic-acid

    go.drugbank.com/drugs/DB16029
    Investigational

    2-(5-fluoro-pentyl)-2-methyl-malonic-acid is under investigation in clinical trial NCT00696943 (18F ML-10 for Early Detection of Response of Brain Metastases to SRS).

  6. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … [L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  7. Drug

    Aminoglutethimide

    go.drugbank.com/drugs/DB00357
    ApprovedWithdrawn

    An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 Inducers
  8. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. … It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel.

  9. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … one-hour infusion twice-a-year following the starting dose.

  10. Indication

    Gastro-esophageal Reflux Disease (GERD)

    go.drugbank.com/conditions/DBCOND0077290
    Drugs: Alginic acid · Aluminum hydroxide · Belladonna · Calcium carbonate · Cimetidine · Cinitapride +14 more